Letter: Consensus in international guidelines when discontinuing nucleos(t)ide analogue therapy in patients with chronic hepatitis B

Aliment Pharmacol Ther. 2023 Nov;58(9):954-955. doi: 10.1111/apt.17680.

Authors

Steven Trinh¹, Bridgette Andrew¹, Stephen Bloom^{1

2}, Rohit Sawhney^{1

2}

Affiliations

¹ Department of Gastroenterology, Eastern Health, Box Hill, Victoria, Australia.
² Eastern Health Clinical School, Monash University, Box Hill, Victoria, Australia.

PMID: 37831539
DOI: 10.1111/apt.17680

No abstract available

Publication types

Letter
Comment

MeSH terms

Antiviral Agents / therapeutic use
Consensus
Hepatitis B Surface Antigens
Hepatitis B e Antigens
Hepatitis B virus
Hepatitis B, Chronic* / drug therapy
Humans
Nucleosides / therapeutic use
Treatment Outcome

Substances

Antiviral Agents
Hepatitis B e Antigens
Nucleosides
Hepatitis B Surface Antigens